Ardelyx (STU:41X) E10: €-1.25 (As of Mar. 2026)


STU:41X Ardelyx Inc STU:41X
73 GF Score
Price €4.62
GF Value €8.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx E10?

Ardelyx STU:41X -1.07% 73 E10 is €-1.25 as of Mar. 2026. GuruFocus rates STU:41X with a GF Score™ of 73/100 and a GF Value™ of €8.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ardelyx's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.25 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-12), Ardelyx's current stock price is €4.62. Ardelyx's E10 for the quarter that ended in Mar. 2026 was €-1.25. Ardelyx's Shiller PE Ratio of today is .


Ardelyx  (STU:41X) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ardelyx E10 Related Terms


Ardelyx E10 Historical Data

* Premium members only.

The historical data trend for Ardelyx's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx E10 Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.18 -1.34 -1.49 0.00

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.38 0.00 0.00 -1.25

STU:41X vs AVLN, INBX, JBIO: E10 Comparison

For the Biotechnology subindustry, Ardelyx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ardelyx's Shiller PE Ratio falls into.


STU:41X
73GF Score
Ardelyx Inc STU:41X
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ardelyx's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.13/330.2130*330.2130
=-0.130

Current CPI (Mar. 2026) = 330.2130.

Ardelyx Quarterly Data

per share eps CPI Adj_EPS
201606 -0.739 241.018 -1.012
201609 -0.579 241.428 -0.792
201612 -0.616 241.432 -0.843
201703 -0.552 243.801 -0.748
201706 -0.481 244.955 -0.648
201709 -0.369 246.819 -0.494
201712 0.177 246.524 0.237
201803 -0.292 249.554 -0.386
201806 -0.360 251.989 -0.472
201809 -0.334 252.439 -0.437
201812 -0.396 251.233 -0.520
201903 -0.372 254.202 -0.483
201906 -0.363 256.143 -0.468
201909 -0.336 256.759 -0.432
201912 -0.243 256.974 -0.312
202003 -0.226 258.115 -0.289
202006 -0.249 257.797 -0.319
202009 -0.170 260.280 -0.216
202012 -0.263 260.474 -0.333
202103 -0.286 264.877 -0.357
202106 -0.374 271.696 -0.455
202109 -0.357 274.310 -0.430
202112 -0.274 278.802 -0.325
202203 -0.191 287.504 -0.219
202206 -0.180 296.311 -0.201
202209 -0.141 296.808 -0.157
202212 0.057 296.797 0.063
202303 -0.121 301.836 -0.132
202306 -0.074 305.109 -0.080
202309 0.028 307.789 0.030
202312 -0.119 306.746 -0.128
202403 -0.101 312.332 -0.107
202406 -0.065 314.175 -0.068
202409 0.000 315.301 0.000
202412 0.019 315.605 0.020
202503 -0.157 319.799 -0.162
202506 -0.069 322.561 -0.071
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 -0.130 330.213 -0.130

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.25 mean?
Ardelyx (STU:41X) has a E10 of €-1.25 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ardelyx and its competitors.
Is Ardelyx's E10 too high?
Ardelyx's current E10 is €-1.25. Overall, Ardelyx has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's E10 compare to AVLN and INBX?
Ardelyx's E10 of €-1.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ardelyx and its competitors. Ardelyx's current E10 is €-1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (STU:41X) is currently considered Possible Value Trap. The stock's GF Value™ is €8.90, compared to a current price of €4.62 — trading 48.1% below its estimated fair value. The current E10 is €-1.25. Ardelyx's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ardelyx (STU:41X), the current E10 is €-1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (STU:41X) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of €4.62 is trading 48.1% below its estimated GF Value™ of €8.90. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for STU:41X:

  • E10: €-1.25
  • GF Value™: €8.90 vs. price of €4.62 (48.1% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the STU:41X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ardelyx Business Description

Other Exchanges ARDX:USAARDX:Mexico
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
73GF Score

Get the complete analysis for STU:41X

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.62
Price
€8.90
GF Value